Tesaro (TSRO) PT Raised to $139 at Wedbush

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. VRNS
2. CRWV
3. JBHT
4. SCHW
5. TSLA
6. GPRK
7. TRV
8. TFC
9. SPY
10. PNC

Go back to Tesaro (TSRO) PT Raised to $139 at Wedbush

Myriad’s myChoice® HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib

October 8, 2016 2:30 AM EDT

SALT LAKE CITY, Oct. 08, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today... More

TESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016

October 8, 2016 2:15 AM EDT

Simultaneous presentation of data at ESMO and publication online in the New England Journal of MedicineTESARO Investor Webcast to be Held at 7:00 PM CET / 1:00 PM EDT

COPENHAGEN, Oct. 08, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, and ENGOT, the European Network for Gynaecological Oncological Trial groups, today announced the presentation of the niraparib Phase 3 ENGOT-OV16/NOVA clinical trial results at the ESMO 2016 Congress, the congress of the European Society for Medical Oncology (ESMO), by Dr.... More